Stay updated with breaking news from Hans Hull. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Pliant Therapeutics (NASDAQ:PLRX – Get Free Report)‘s stock had its “buy” rating restated by stock analysts at HC Wainwright in a research note issued on Wednesday, Benzinga reports. They presently have a $48.00 price target on the stock. HC Wainwright’s price target would suggest a potential upside of 190.56% from the stock’s previous close. Several […]
Pliant Therapeutics (NASDAQ:PLRX – Get Free Report)‘s stock had its “buy” rating reiterated by equities research analysts at HC Wainwright in a research report issued on Wednesday, Benzinga reports. They currently have a $48.00 price objective on the stock. HC Wainwright’s price objective suggests a potential upside of 190.56% from the company’s previous close. A […]
Pliant Therapeutics (NASDAQ:PLRX – Get Free Report)‘s stock had its “buy” rating restated by stock analysts at HC Wainwright in a research note issued on Wednesday, Benzinga reports. They presently have a $48.00 price target on the stock. HC Wainwright’s price target would suggest a potential upside of 190.56% from the stock’s previous close. Several […]
Rhenman & Partners Asset Management AB acquired a new stake in shares of Pliant Therapeutics, Inc. (NASDAQ:PLRX – Free Report) in the third quarter, according to the company in its most recent filing with the SEC. The firm acquired 330,635 shares of the company’s stock, valued at approximately $5,733,000. Rhenman & Partners Asset Management AB […]
Pliant Therapeutics, Inc. (NASDAQ:PLRX – Get Free Report)’s stock price reached a new 52-week low on Wednesday . The stock traded as low as $14.12 and last traded at $14.15, with a volume of 14016 shares trading hands. The stock had previously closed at $14.78. Analyst Ratings Changes Several equities analysts recently issued reports on […]